Literature DB >> 26391212

Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer.

Koji Matsuo1,2, Jocelyn Garcia-Sayre1, Fabiola Medeiros3, Jennifer K Casabar1, Hiroko Machida1, Aida Moeini1, Lynda D Roman1,2.   

Abstract

BACKGROUND AND OBJECTIVES: To determine the significance of depth and extent of lymphovascular space invasion (LVSI) on lymph node metastasis and recurrence in endometrial cancer.
METHODS: A case-control study was conducted to examine LVSI-positive (n = 70) and LVSI-negative (n = 641) stage I-III endometrial cancer cases that underwent hysterectomy-based surgical staging. The risk of lymph node metastasis and distant recurrence was estimated based on LVSI patterns.
RESULTS: In multivariate analysis, deep (>50% invasion), and extensive (≥7 foci/slide) LVSI patterns had a significantly increased risk of lymph node metastasis (incidence 57.6% and 72.7%, odds ratio 33.8 and 49.9, respectively, P < 0.001) as compared to other traditional uterine factors (>50% myometrial tumor invasion, cervical stromal invasion, and adnexal involvement: incidence range 30.4-37.9%, odds ratio range 3.80-7.03). Deep and extensive of LVSI patterns were both significantly correlated to distant recurrence (P < 0.001). Among women who received postoperative chemotherapy, deep and extensive LVSI patterns did not have increased risks for distant recurrence compared to no LVSI (P = 0.47 and 0.32, respectively). Among women who received postoperative radiotherapy, the depth of LVSI was significantly associated with recurrence outside the radiated field (P = 0.02).
CONCLUSIONS: Depth and extent of LVSI are important predictors for lymph node metastasis and distant recurrence in endometrial cancer.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemotherapy; endometrial cancer; lymph node metastasis; lymphovascular space invasion; radiotherapy; recurrence

Mesh:

Year:  2015        PMID: 26391212     DOI: 10.1002/jso.24049

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma.

Authors:  Yushen Qian; Erqi L Pollom; Chika Nwachukwu; Kira Seiger; Rie von Eyben; Ann K Folkins; Elizabeth A Kidd
Journal:  Gynecol Oncol       Date:  2017-07-11       Impact factor: 5.482

2.  MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer.

Authors:  Sophia C Kamran; Matthias M Manuel; Paul Catalano; Linda Cho; Antonio L Damato; Larissa J Lee; Ehud J Schmidt; Akila N Viswanathan
Journal:  Brachytherapy       Date:  2017-08-17       Impact factor: 2.362

3.  Molecular Characterization of an Endometrial Endometrioid Adenocarcinoma Metastatic to a Thyroid Hürthle Cell Adenoma Showing Cancerization of Follicles.

Authors:  Amir H Afrogheh; Emily Meserve; Peter M Sadow; Antonia E Stephen; Vânia Nosé; Suzanne Berlin; William C Faquin
Journal:  Endocr Pathol       Date:  2016-09       Impact factor: 3.943

4.  Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.

Authors:  Koji Matsuo; Shinya Matsuzaki; David J Nusbaum; Hiroko Machida; Yoshikazu Nagase; Brendan H Grubbs; Lynda D Roman; Jason D Wright; Philipp Harter; Maximilian Klar
Journal:  Eur J Cancer       Date:  2020-05-17       Impact factor: 9.162

5.  Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.

Authors:  Koji Matsuo; Malcolm S Ross; Mayu Yunokawa; Marian S Johnson; Hiroko Machida; Kohei Omatsu; Merieme M Klobocista; Dwight D Im; Shinya Satoh; Tsukasa Baba; Yuji Ikeda; Stephen H Bush; Kosei Hasegawa; Erin A Blake; Munetaka Takekuma; Masako Shida; Masato Nishimura; Sosuke Adachi; Tanja Pejovic; Satoshi Takeuchi; Takuhei Yokoyama; Yutaka Ueda; Keita Iwasaki; Takahito M Miyake; Shiori Yanai; Tadayoshi Nagano; Tadao Takano; Mian Mk Shahzad; Frederick R Ueland; Joseph L Kelley; Lynda D Roman
Journal:  Surg Oncol       Date:  2019-02-07       Impact factor: 3.279

6.  L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.

Authors:  Daniela de Freitas; Fernando Nalesso Aguiar; Cristina Anton; Carlos Eduardo Bacchi; Jesus Paula Carvalho; Filomena Marino Carvalho
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

7.  Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study.

Authors:  Gitte Ørtoft; Lisa Lausten-Thomsen; Claus Høgdall; Estrid S Hansen; Margit Dueholm
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

8.  Clinicopathological characteristics and treatment of patients with high-grade endometrial stromal sarcoma: A retrospective study of 40 cases.

Authors:  Huimin Bai; Fang Yuan; Bing Liang; Hengzi Sun; Yutao Gao; Mulan Jin; Xiaoming Xing
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

9.  Association of Myometrial Invasion With Lymphovascular Space Invasion, Lymph Node Metastasis, Recurrence, and Overall Survival in Endometrial Cancer: A Meta-Analysis of 79 Studies With 68,870 Patients.

Authors:  Jianzhang Wang; Ping Xu; Xueying Yang; Qin Yu; Xinxin Xu; Gen Zou; Xinmei Zhang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

10.  Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

Authors:  Anna L Beavis; Ting-Tai Yen; Rebecca L Stone; Stephanie L Wethington; Caitlin Carr; Ji Son; Laura Chambers; Chad M Michener; Stephanie Ricci; Wesley C Burkett; Debra L Richardson; Allison-Stuart Staley; Susie Ahn; Paola A Gehrig; Diogo Torres; Sean C Dowdy; Mackenzie W Sullivan; Susan C Modesitt; Catherine Watson; Ashely Veade; Jessie Ehrisman; Laura Havrilesky; Angeles Alvarez Secord; Amy Loreen; Kaitlyn Griffin; Amanda Jackson; Akila N Viswanathan; Leah R Jager; Amanda N Fader
Journal:  Gynecol Oncol       Date:  2020-01-14       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.